In another trial, 87% of the participants preferred transdermal patches over oral medication, showing the need for transdermal drug delivery systems (TDDS) for GLP-1 drugs
Antonoff MB, Hofstetter WL, Correa AM, Bell JM, Sepesi B, Rice DC, Vaporciyan AA, Walsh GL, Mehran RJ, Swisher SG , Meyers BF
They claim $449,000 in lost R&D, $107,000 in confirmed lost sales, and $85,000 in written-off inventory
In addition, we performed sensitivity analyses, including adverse effects at the beginning and at any time point during the evaluation visit as additional covariates with an interaction term in the statistical model
with 1,025 protein targets significant under FDR control)
Lower Side Effects Nausea and GI symptoms are typically minimal at micro-dose levels